Page 20 - Eceptor News Today

A mechanism that led some patients to experience cases of deadly clotting following some types of Covid-19 vaccination has been identified in new research.

About 283 million people worldwide suffer from alcohol use disorder, a debilitating health challenge for which limited therapeutic options are available. The cost to society is estimated at greater than $2 trillion annually.

Engineers at the University of California San Diego have developed modular nanoparticles that can be easily customized to target different biological entities such as tumors, viruses or toxins.

Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction. Researchers recommend careful monitoring and possibly discontinuing these drugs during pregnancy despite their effectiveness against cancer.

The efficacy of the bivalent Pfizer-BioNTech COVID-19 messenger ribonucleic acid (mRNA) vaccine BNT162b2 BA.4/5.

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

Researchers investigated whether Tongxinluo, a Chinese medicinal compound, could improve clinical outcomes among ST-segment elevation myocardial infarction patients.

Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.